ClinConnect ClinConnect Logo
Search / Trial NCT00629304

Multicenter Assessment of the PDA-FIT System in Type 1 Diabetic Patients

Launched by CENTRE D'ETUDES ET DE RECHERCHE POUR L'INTENSIFICATION DU TRAITEMENT DU DIABÈTE · Mar 4, 2008

Trial Information

Current as of May 22, 2025

Completed

Keywords

Type 1 Diabetes Pda Phone (Personal Digital Assistant) Hb A1c

ClinConnect Summary

Secondary Objectives :

1. To assess the improvement of blood glucose control and quality of life in patients using the PDA-FIT system
2. To assess the improvement in diabetes care provided by the use of the PDA-FIT system
3. Satisfaction of patients and physicians towards the PDA-FIT system

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • type 1 diabetes mellitus for ≥ 12 months or more (including C-peptide negative secondary diabetes)
  • age \> 18 y.o.
  • intensive insulin basal-bolus therapy for ≥ 6 months. At inclusion, patients should be treated, either with a combination of a basal, long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
  • chronically uncontrolled diabetes with HbA1c ≥ 8 % during the past 12 months and at inclusion
  • Exclusion Criteria:
  • patient with unstable associated evolutive pathology
  • patient who need a more frequent diabetic follow up (than in the protocol)
  • patient with a education teaching within the 3 months before inclusion
  • patient with a hemoglobinopathy
  • patient with toxicomania, alcoholism or psychological troubles
  • type 2 diabetes patients
  • patient who don't need strict metabolic objectives
  • pregnant or parturient women
  • person with no freedom (prisoner)

About Centre D'etudes Et De Recherche Pour L'intensification Du Traitement Du Diabète

The Centre d'Études et de Recherche pour l'Intensification du Traitement du Diabète (CERITD) is a leading clinical trial sponsor dedicated to advancing diabetes treatment through innovative research and rigorous clinical studies. With a focus on improving patient outcomes, CERITD collaborates with healthcare professionals, academic institutions, and industry partners to explore new therapeutic strategies and enhance existing interventions for diabetes management. By prioritizing scientific excellence and patient-centric approaches, CERITD aims to contribute significantly to the understanding and treatment of diabetes, ultimately fostering improved quality of life for individuals affected by this chronic condition.

Locations

Pessac, , France

Saint Etienne, , France

Montpellier, , France

Paris, , France

Lille, , France

Paris, , France

Nantes, , France

Toulouse, , France

Lyon, , France

Belfort, , France

Besancon, , France

Corbeil Essonnes, , France

Grenoble, , France

Marseille, , France

Nancy, , France

Paris, , France

Rennes, , France

Strasbourg, , France

Patients applied

0 patients applied

Trial Officials

Pierre Yves BENHAMOU, MD PHD

Study Chair

University Hospital, Grenoble

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials